Latest SWOG Stories
By the National Cancer Institute BETHESDA, Md., Dec.
FDA Removes Clinical Hold on Phase 2 Clinical Trial SAN DIEGO, Sept. 18, 2014 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that the U.S.
The Lung-MAP trial uses a multi-drug, targeted screening approach to match patients with promising new cancer treatments based on their unique tumor profiles BETHESDA, Md., June 16,
- Large; stout; burly.